T.Man Pharmaceutical PCL (BKK:TMAN)

Market Cap	4.52B -1.7%
Revenue (ttm)	2.53B +13.5%
Net Income	523.07M +16.1%
EPS	1.31 -0.4%
Shares Out	400.00M
PE Ratio	8.64
Forward PE	8.97
Dividend	0.32 (2.71%)
Ex-Dividend Date	May 8, 2026

Volume	281,275
Average Volume	147,356
Open	11.80
Previous Close	11.80
Day's Range	11.20 - 11.90
52-Week Range	9.95 - 13.60
Beta	n/a
RSI	24.33
Earnings Date	May 14, 2026

About T.Man Pharmaceutical PCL

T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties’ Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatological, mouth, and throat products. The company also provides herbal and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 944
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: TMAN

Financial Performance

In 2025, T.Man Pharmaceutical PCL's revenue was 2.53 billion, an increase of 13.48% compared to the previous year's 2.23 billion. Earnings were 523.07 million, an increase of 16.06%.